<unk>  is a cholinesterase inhibitor that is FDA approved for the treatment of myasthenia gravis.   Common adverse reactions include nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis diaphoresis, muscle cramps and weakness.
Pyridostigmine Bromide
Neostigmine methylsulfate
Physostigmine
Neostigmine
Suxamethonium chloride
Benzethonium chloride
Mecamylamine
Atropine 